The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
SOHO 2024 live congress feed
Stay up to date with the latest developments in Multiple Myeloma from the SOHO 2024 Annual Meeting with our live social media coverage.
CONGRESS | #SOHO2024 | POSTER@SagarLonialMD @WinshipAtEmory shares data from the CC-220-MM-001 trial of IberVd in transplant-ineligible NDMM.
— Multiple Myeloma Hub (@MM_Hub) September 6, 2024
ORR 100%, ≥CR 56.25%, MRD-neg 43%, infections 76.5%, Grade 3/4 infections 35.3%, neutropenia 35.3%, Grade 3/4 neutropenia 23.5%.#mmsm… pic.twitter.com/oT9xvGXW88
CONGRESS | #SOHO2024 | POSTER@DrKrinaPatel @MDAndersonNews shares results from a subanalysis of data from Black patients enrolled in the KarMMa-3 study.
— Multiple Myeloma Hub (@MM_Hub) September 6, 2024
ORR 89%, sCR 50%, median DoR 17.5 mo, median PFS 20.3 mo, 9-mo PFS 77%, CRS 82%, iiNT 12%. The clinical benefit of ide-cel… pic.twitter.com/XIwsCdf6Q9
CONGRESS | #SOHO2024
— Multiple Myeloma Hub (@MM_Hub) September 5, 2024
Meletios Dimopoulos @thanosdimop presents an analysis of MRD from the phase III PERSEUS study of D-VRd for transplant-eligible NDMM. Sustained MRD-neg rates were improved with D-VRd across all subgroups and at >12 months were approximately double compared to… pic.twitter.com/b3P5K3c7QC
CONGRESS | #SOHO2024@DoctorAKrishnan @cityofhopeoc discusses sequencing and resistance associated with T-cell engagers in #MultipleMyeloma. Krishnan suggests methods to effectively sequence T-cell engagers using different targets and modalities, with potential for future… pic.twitter.com/VfcMVRg2M6
— Multiple Myeloma Hub (@MM_Hub) September 5, 2024
CONGRESS | #SOHO2024
— Multiple Myeloma Hub (@MM_Hub) September 5, 2024
Meletios Dimopoulos @thanosdimop presents on the treatment options for first relapse in #MultipleMyeloma; sharing data from the latest clinical trials of approved and investigational agents. #mmsm #myeloma pic.twitter.com/56vO5YjdkS
CONGRESS | #SOHO2024
— Multiple Myeloma Hub (@MM_Hub) September 5, 2024
Suzanne Lentzsch @Slentzsch @columbiacancer discusses the definition and treatment of HR-NDMM and functional HR #MultipleMyeloma. High-remission rates are possible but duration is often short, highlighting an unmet need amongst these patients.#mmsm #myeloma pic.twitter.com/lugFWzF3f5
CONGRESS | #SOHO2024
— Multiple Myeloma Hub (@MM_Hub) September 5, 2024
Saad Usmani @szusmani @MSKCancerCenter argues that there are too many unknowns for CAR T-cell therapies in earlier lines to apply this to all patients, furthermore there are novel therapies being investigated for early relapsed setting that may influence… pic.twitter.com/qDmvM3Eeq4
CONGRESS | #SOHO2024@DrKrinaPatel @MDAndersonNews debates for the use of CAR T in the early relapsed setting, concluding that there is a place for CAR T in both the early and late relapsed setting, with latest data showing evidence for unprecedented high efficacy rates in both… pic.twitter.com/ROvvq420gF
— Multiple Myeloma Hub (@MM_Hub) September 5, 2024
CONGRESS | #SOHO2024@AjayNookaMD @EmoryMedicine discusses whether quadruplet regimens should be used for all patients with NDMM; concluding that upfront quad therapies are the standard of care for both transplant eligible and ineligible patients. #mmsm #myeloma pic.twitter.com/skqe4bXukY
— Multiple Myeloma Hub (@MM_Hub) September 5, 2024
Only 1 day to go!
— Multiple Myeloma Hub (@MM_Hub) September 3, 2024
The #MultipleMyeloma Hub will be covering #SOHO2024.
Sep 4–7
Houston, US, and online
We’ll be providing live social media coverage.
Keep an eye on our socials to see the latest updates! #mmsm @SocietyofHemOnc pic.twitter.com/dMwAWG5uFC
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content